PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	123-132	apolipoprotein B	Homo sapiens	53-57	
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	134-141	apolipoprotein B	Homo sapiens	53-57	
11853686-1	2002	We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT).	avasimibe	143-152	apolipoprotein B	Homo sapiens	85-89	
11853686-1	2002	We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT).	avasimibe	154-161	apolipoprotein B	Homo sapiens	85-89	
11853686-4	2002	Pulse-chase studies showed that the treatment with avasimibe induced a >75% decrease in apoB secretion relative to control, but initially enhanced the protein stability and cellular accumulation of apoB.	avasimibe	51-60	apolipoprotein B	Homo sapiens	91-95	
11853686-4	2002	Pulse-chase studies showed that the treatment with avasimibe induced a >75% decrease in apoB secretion relative to control, but initially enhanced the protein stability and cellular accumulation of apoB.	avasimibe	51-60	apolipoprotein B	Homo sapiens	201-205